Home › Research › Cognitive tests and assessment
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL et al.. JAMA psychiatry, 2018-01-01
Topic: Amyloid, tau and blood-test diagnosis
Importance Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials. Objective To investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jansen, W. J., Ossenkoppele, R., Tijms, B. M., Fagan, A. M., Hansson, O., Klunk, W. E., et al. (2018). Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA psychiatry. https://doi.org/10.1001/jamapsychiatry.2017.3391
Vancouver
Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, et al. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA psychiatry. 2018. doi:10.1001/jamapsychiatry.2017.3391. PMID: 29188296.
BibTeX
@article{jansen2018-29188296,
author = {Jansen, W. J. and Ossenkoppele, R. and Tijms, B. M. and Fagan, A. M. and Hansson, O. and Klunk, W. E. and van der Flier, W. M. and Villemagne, V. L. and others},
title = {{Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia}},
journal = {JAMA psychiatry},
year = {2018},
doi = {10.1001/jamapsychiatry.2017.3391},
pmid = {29188296},
url = {https://doi.org/10.1001/jamapsychiatry.2017.3391}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.
- Objective To investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia.
- Design, setting, and participants This cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study.
- Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests.
Why it matters
This cross-sectional study examined whether amyloid-beta aggregation is associated with cognitive functioning in 2908 people with normal cognition and 4133 with mild cognitive impairment. It describes an association only and does not test any treatment, so it cannot show how to treat, cure, or prevent Alzheimer's disease.
Study details
- Study designcross-sectional
- Participants2,908
- Evidence strengthLow
How this study scored 62/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA psychiatry) |
| Journal's citation record | 3 / 4 | JAMA Psychiatry: journal h-index 256 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,908 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 141 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 14.1 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 4 / 6 | Cited 15.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 10 other studies in this library |
| Still being cited | 1 / 4 | Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Oliver Peters: h-index 63 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 99 institution(s) in 20 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29188296) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamapsychiatry.2017.3391
- PubMed: 29188296
- Original source →
- Free full text: JAMA Psychiatry →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Cognitive tests and assessment
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.